Overview

Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation

Status:
Not yet recruiting

Trial end date:
2026-01-31

Target enrollment:

Participant gender:

Summary

This is a Phase 1, open-label, single center study of short-course oral venetoclax therapy prior to non-myeloablative conditioning with fludarabine and cyclophosphamide in subjects with haematological malignancies who are planned for allogeneic stem cell transplantation (alloSCT). The primary study objective is to determine the safety and maximum tolerated dose of venetoclax when used in combination with fludarabine and cyclophosphamide conditioning. Secondary objectives were to evaluate the transplant outcomes and donor/recipient engraftment of this regimen.

Phase:

Phase 1

Details

Lead Sponsor:

Melbourne Health

Treatments:

Cyclophosphamide
Fludarabine
Venetoclax